Insulet Co. (NASDAQ:PODD) Shares Bought by Empowered Funds LLC

Empowered Funds LLC lifted its holdings in Insulet Co. (NASDAQ:PODD) by 357.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,327 shares of the medical instruments supplier’s stock after purchasing an additional 3,381 shares during the period. Empowered Funds LLC’s holdings in Insulet were worth $1,130,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in PODD. Exchange Traded Concepts LLC acquired a new position in Insulet in the third quarter worth approximately $121,000. Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in shares of Insulet by 3.0% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,453 shares of the medical instruments supplier’s stock worth $1,502,000 after acquiring an additional 188 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 58 shares during the last quarter. Raymond James & Associates raised its position in shares of Insulet by 3.8% during the third quarter. Raymond James & Associates now owns 37,456 shares of the medical instruments supplier’s stock worth $8,718,000 after purchasing an additional 1,367 shares during the period. Finally, Chicago Capital LLC lifted its holdings in shares of Insulet by 3.4% during the third quarter. Chicago Capital LLC now owns 168,434 shares of the medical instruments supplier’s stock valued at $39,203,000 after purchasing an additional 5,557 shares during the last quarter.

Insider Buying and Selling

In related news, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Lauren Budden sold 915 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares in the company, valued at $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by corporate insiders.

Insulet Stock Down 0.6 %

PODD opened at $280.56 on Monday. The company has a market capitalization of $19.68 billion, a PE ratio of 48.04, a price-to-earnings-growth ratio of 3.61 and a beta of 1.23. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The business has a 50-day moving average of $271.74 and a 200-day moving average of $244.73.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Citigroup lifted their price target on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Barclays lifted their target price on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. Morgan Stanley upped their price target on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. Wells Fargo & Company lifted their price objective on shares of Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Finally, Canaccord Genuity Group boosted their target price on shares of Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $277.13.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.